Cancer Research
Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Type Population to Support a Future sNDA Submission as the Current Topline Data from the SIENDO Study are Unlikely to Support an sNDA Approval Karyopharm is Encouraged by the SIENDO p53…
Read More
Excerpt from the Press Release: BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ — Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combination therapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with cetuximab for the treatment of KRAS G12C-mutated advanced colorectal cancer. Colorectal cancer is the second most common tumor…
Read More
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Feb. 22, 2022– Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its CNSide™ cerebrospinal…
Read More
Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®. In a real-world analysis of 1,076…
Read More
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency, KIMMTRAK will be the first and only treatment option approved in Europe to treat patients with unresectable or metastatic uveal melanoma KIMMTRAK demonstrated statistically and clinically meaningful overall survival (OS) benefit, hazard ratio of 0.51, with median OS of almost 22 months Excerpt from the…
Read More
Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent Fulgent Genetics’ expertise in high-volume testing powers Epic’s Comprehensive Cancer Profiling Excerpt from the Press Release: SAN DIEGO, Feb. 24, 2022 /PRNewswire/ –Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast…
Read More
38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance setting versus a median OS of 15.0 months with BSC alone BAVENCIO continues to be the first and only immunotherapy to improve survival in the…
Read More
Excerpt from the Press Release: SAN DIEGO, Feb. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the development program, Regen will design and have experiments carried out that will form the initial…
Read More
– Phase III, randomized controlled trial results highlight patient reported outcomes at 10 years’follow-up– TomoTherapy delivered hypofractionated radiotherapy was superior to conventional radiotherapy in maintaining patients’ heart and lung functioning, enabling them to more easily perform daily and leisure time activities, and/or work Excerpt from the Press Release: SUNNYVALE, Calif., Feb. 10, 2022 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY)…
Read More
Data published in Clinical and Translational Radiation Oncology Peer-reviewed clinical case study reported preliminary data on the first-in-human administration of NBTXR3 for the treatment of pancreatic cancer not eligible for surgery, demonstrating feasibility with no treatment-related toxicity Case study provides the first demonstration of local endoscopic delivery of NBTXR3 to a deep visceral tumor, and…
Read More